AI Genetics

AI Genetics, founded in 2017 and headquartered in Lausanne, Switzerland, is a global leader in AI-driven precision medicine.

Reviewed by 7wData
Share Email

On this page

Profile

AI Genetics provides AI-driven genomic data analysis to help clinicians diagnose and treat patients more effectively.

AI Genetics, founded in 2017 and headquartered in Lausanne, Switzerland, is a global leader in AI-driven precision medicine. The company specializes in genomic data analysis, leveraging its proprietary AI platform to assist clinicians in diagnosing and treating patients more effectively. AI Genetics has established a strong presence in over 70 countries, with its technology being used by more than 800 healthcare institutions.

The company went public in 2021, trading on the Nasdaq under the ticker SOPH. In 2025, AI Genetics reported a revenue of $77 million, marking an 18% year-over-year growth, and performed over 391,000 genomic analyses, setting a new company record. The company expects continued growth in 2026, projecting revenues between $92 million and $94 million.

A significant leadership transition occurred in 2026, with Ross Muken promoted to CEO, succeeding co-founder Jurgi Camblong, who transitioned to Executive Chairman. AI Genetics has also formed strategic partnerships, such as with Element Biosciences, to integrate sequencing and AI analytics, enhancing genomic workflows. The company’s focus remains on democratizing access to precision medicine globally, driven by its AI-powered platform and expanding customer base.

Track AI Genetics and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Hospitals and healthcare institutions
  • Clinical research organizations
  • Biopharmaceutical companies
  • Academic medical centers
  • Cancer treatment centers

Publicly disclosed clients

  • Institut Paoli-Calmettes
  • Mount Sinai Health System
  • Christian Medical College

Strengths and what to watch

Strengths

  • Extensive global reach with over 800 healthcare institutions using its platform
  • Strong revenue growth, with a projected 20-22% increase in 2026
  • Strategic partnerships enhancing genomic workflows, such as with Element Biosciences

Watch for

  • Leadership transition with Ross Muken taking over as CEO in 2026
  • Projected adjusted EBITDA loss of $29 million to $32 million in 2026
  • High dependence on the U.S. market for revenue growth

Recent moves

Key Information

Founded
2017
Headquarters
Lausanne, Switzerland

Frequently Asked Questions

What does AI Genetics do?

AI Genetics provides AI-powered genomic data analysis to help clinicians diagnose and treat patients more effectively. Founded in 2017, the Swiss company specializes in precision medicine, serving over 800 healthcare institutions globally through its proprietary AI platform for genomic interpretation.

How does AI Genetics' genomic analysis platform work?

AI Genetics' platform uses proprietary AI algorithms to analyze genomic data, helping clinicians interpret complex genetic information. The technology integrates with sequencing data to provide actionable insights for diagnosis and treatment decisions, particularly in precision medicine applications.

What is AI Genetics' financial performance?

In 2025, AI Genetics reported $77 million revenue with 18% year-over-year growth. The company projects 2026 revenues between $92-$94 million, representing 20-22% growth. However, it anticipates an adjusted EBITDA loss of $29-$32 million for 2026 as it continues expanding.

Who are AI Genetics' key customers?

AI Genetics serves over 800 healthcare institutions globally, including hospitals, cancer centers, and research organizations. Notable clients include Institut Paoli-Calmettes, Mount Sinai Health System, and Christian Medical College. Their platform supports clinical, research, and pharmaceutical applications.

What partnerships has AI Genetics formed?

AI Genetics partnered with Element Biosciences to combine sequencing technology with AI analytics, enhancing genomic workflows. Such collaborations aim to accelerate precision medicine research while expanding the company's technological capabilities and market reach.

Is AI Genetics a publicly traded company?

Yes, AI Genetics went public in 2021 and trades on Nasdaq under ticker SOPH. The company reported performing over 391,000 genomic analyses in 2025, setting a record. Leadership transitioned in 2026 with Ross Muken becoming CEO.

Sources

  1. www.prnewswire.com — 2025 financial results and 2026 guidance
  2. www.prnewswire.com — First quarter 2026 financial results
  3. www.prnewswire.com — Partnership with Element Biosciences
  4. www.prnewswire.com — Series D funding round